Sign in

Erick Lansigan

@thebloodmd.bsky.social
303 followers 698 following 17 posts

Dartmouth Cancer Center, Hematologist, Lymphoma, Leukemia, Clinical Trials, Fellowship Program Director, Healthy Lifestyles. Social Justice, Health Equity, Global Health. Act Locally, Think Globally.

PostsRepliesMedia
Erick Lansigan @thebloodmd.bsky.social · 11/07/2025
I’m riding 150 miles to support the Dartmouth Cancer Center! Day 1 tomorrow! Please support me in my emotional return to cycling! getinvolved.dartmouth-hitchcock.org/site/TR/Frie...
getinvolved.dartmouth-hitchcock.org
The Prouty 2025
Prouty
030
Reposted by Erick Lansigan
Miguel Perales MD @drmiguelperales.bsky.social · 10/12/2024
If you joined @bsky.app during @ash-hematology.bsky.social #ASH24 here’s a starter pack for transplant, cell & gene therapy #bmtsm #CARTcells #generherapy go.bsky.app/7xxh8WW
02813
Reposted by Erick Lansigan
Yale Cancer Center @yalecancer.bsky.social · 10/12/2024
Dr. Jessica Stempel shares results from the phase 2 BLAST trial in acute myeloid leukemia #AML showing that the addition of pembro to azacitidine plus venetoclax was associated with worse outcomes #ASH24. ash.confex.com/ash/2024/web... @yale-hematology.bsky.social
021
Reposted by Erick Lansigan
OncLive @onclive.bsky.social · 10/12/2024
Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis @ash-hematology.bsky.social #ASH24 #mpnsm #oncology www.onclive.com/view/navtema...
onclive.com
Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
051
Reposted by Erick Lansigan
OncLive @onclive.bsky.social · 10/12/2024
Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR @ash-hematology.bsky.social #ASH24 #lymphoma #oncology www.onclive.com/view/autolog...
onclive.com
Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR
Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.
052
Erick Lansigan @thebloodmd.bsky.social · 10/12/2024
Camp ASH is a flash Four days to present data Saturating minds #ASHHaiku #ASH24
140
Erick Lansigan @thebloodmd.bsky.social · 10/12/2024
Sun setting on my #ASH24. Invigorated to pursue new leads. Until next year, friends!
140
Erick Lansigan @thebloodmd.bsky.social · 10/12/2024
Handful of Monday abstracts Dartmouth Cancer Center has worked on at #ASH24 spanning mastocytosis, CLL and hemolytic anemia. Thank you to our patients, collaborators, and pharma partners at in advancing cancer care and gaining new knowledge.
040
Erick Lansigan @thebloodmd.bsky.social · 09/12/2024
Amazing talk in the #ASH24 Health Equity Studio today by @kekoamdphd.bsky.social. Wonderful to see and started the day off brightly!
282
Erick Lansigan @thebloodmd.bsky.social · 08/12/2024
One idea for creating an environment of #inclusion is to provide interpreters for the speakers whom English is not their native language especially during question and answers. #ash24
000
Erick Lansigan @thebloodmd.bsky.social · 08/12/2024
Well done study! “Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from 'FOLL12' Phase III Trial of the Fondazione Italiana Linfoma” Congrats to Simone Ferrero and the group. My favorite abstract of the day! #ash24
010
Erick Lansigan @thebloodmd.bsky.social · 07/12/2024
Proud to represent #ASH24 and Dartmouth Cancer Center, my institutional homes. Thank you for all the opportunities you’ve given me.
010
Erick Lansigan @thebloodmd.bsky.social · 07/12/2024
We shouldn’t ignore the many #unhoused people in SD during #ash24. I started reading this book on the plane. Finding solutions for housing insecurity is on the same scale as finding a cure for cancer.
010
Erick Lansigan @thebloodmd.bsky.social · 07/12/2024
Kicked off #ASH24 with a bike ride, coffee, and ferry out to Coronado Island with some great friends. I vote San Diego as the best place for ASH.
070
Erick Lansigan @thebloodmd.bsky.social · 07/12/2024
Has anyone written about migrating #MedTwitter over to #Medsky? Good article on #bluesky. www.nytimes.com/2024/12/07/o...
nytimes.com
Opinion | Bluesky Is Different From X. For Now.
Users are looking for a more curated experience on a platform that is not constantly trying to get them to interact with brands.
050
Erick Lansigan @thebloodmd.bsky.social · 05/12/2024
My #ASHThrowback is from 1997 in San Diego when I was a lab tech with @roberta_kato in Dr . David Rawlings lab where we were studying gene therapy for BTK in XLA. Now we are trying to inhibit and degrade #BTK and #genetherapy finally made it in lymphoma #CART and sickle. I was hooked then and now.
130
Erick Lansigan @thebloodmd.bsky.social · 05/12/2024
I wonder how people are using X and able to filter out the noise? The energy definitely shifted when it became X. When I joined Twitter I had one account for everything. #MedSky sounds much better then MedTwitter or MedX. The Sky represents hope and expansiveness, while X signifies elimination.
020
Erick Lansigan @thebloodmd.bsky.social · 05/12/2024
Hello #ASH24! Can ASH help create starter packs of anyone who posts on hashtag #ASH24 on a daily basis? @ash-hematology.bsky.social
000
Erick Lansigan @thebloodmd.bsky.social · 05/12/2024
I’m enjoying the migration to @bsky.app from X as TheBloodMD. No better place than #ASH24 to pick up followers, share opinions, and generate new ideas. Until there is critical mass on #medsky I will still monitor X. See you on both!
070
Erick Lansigan @thebloodmd.bsky.social · 05/12/2024
@thebloodmd.bsky.social is looking forward to #ash24 #medsky #hemesky #oncsky and growing a new platform. Who will be my first follower? 😊
240